REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study was, starting from the Italian clinical practice in liver
transplantation, to optimize the immunosuppressive therapy, considering specific patient
characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma
(HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor
(CNI)-withdrawal regimen was evaluated in comparison with a CNI-minimization regimen.